NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) („NeuroSense“), a company developing novel treatments for severe neurodegenerative diseases announced today a collaboration in Alzheimer’s Disease (AD) drug development with Genetika+, a leader in precision medicine for psychiatry and neurology. The multi-phase collaboration, which will commence in NeuroSense’s currently ongoing Phase 2 AD clinical trial, leverages Genetika+’s state-of-the-art technology that derives frontal cortex neurons from individual patients‘ blood to quantify drug-induced neuronal plasticity in vitro. Distinguished by its innovative approach, NeuroSense’s PrimeC therapy stands out in the landscape of AD treatments. Unlike conventional methods that predominantly target amyloid-beta (A?), PrimeC adopts a multi-targeted strategy, concurrently addressing A? aggregation, TDP-43, and other key disease-related pathologies. This unique approach not only diversifies the therapeutic targets but also offers the potential for more potent treatment outcomes.

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) („NeuroSense“), a company developing novel treatments for severe neurodegenerative diseases announced today a collaboration in Alzheimer’s Disease (AD) drug development with Genetika+, a leader in precision medicine for psychiatry and neurology. The multi-phase collaboration, which will commence in NeuroSense’s currently ongoing Phase 2 AD clinical trial, leverages Genetika+’s state-of-the-art technology that derives frontal cortex neurons from individual patients‘ blood to quantify drug-induced neuronal plasticity in vitro. Distinguished by its innovative approach, NeuroSense’s PrimeC therapy stands out in the landscape of AD treatments. Unlike conventional methods that predominantly target amyloid-beta (A?), PrimeC adopts a multi-targeted strategy, concurrently addressing A? aggregation, TDP-43, and other key disease-related pathologies. This unique approach not only diversifies the therapeutic targets but also offers the potential for more potent treatment outcomes.

Immunovia (NASDAQ Stockholm: IMMNOV), the diagnostics company with the mission to increase pancreatic cancer survival through early detection, today?announces its next-generation pancreatic cancer test achieved both the primary and secondary endpoints in a model-development study.  In the study, Immunovia’s next-generation test demonstrated specificity of 98 percent and sensitivity of 75 percent in detecting early stage (1 and 2) pancreatic ductal adenocarcinoma (PDAC), a very aggressive and the most common form of pancreatic cancer. The Immunovia test was also significantly more accurate than CA19-9, the biomarker commonly used to detect pancreatic cancer.  Importantly, these results confirm the technical advancement of the next-generation test over Immunovia’s first-generation test, IMMray PanCan-d. The next-generation test includes high-performing protein biomarkers, making the test less reliant on CA19-9. This is a major achievement as around 10 percent of patients, including many patients of African ancestry, do… 

Legacy coronavirus biochemistry was overlooked that governs spike protein toxicity, key morbidities, risk factors and therapeutic responses. TrialSite News features a paper published today in Viruses (Basel), authored by an international team of researchers, including two fellows of their nations‘ academies of sciences (Colleen Aldous, senior author Wendy Hoy) and others who participated in Nobel prize-honored research (Thomas Borody, Morimasa Yagisawa). The publication reveals how coronavirus biochemistry well-established over past decades governs the morbidities of COVID-19, risk factors and therapeutic approaches. The glycan monomer sialic acid, ubiquitous on eukaryotic cell surfaces, serves as the initial attachment point to host cells for the COVID–19 virus—SARS–CoV–2—as well as for other coronaviruses. The virus can then slide over to ACE2 for cell entry. SARS–CoV–2 spike protein attaches particularly tightly to the dense sialic acid coatings on the trillions of red blood cells (RBCs), platelets and endothelial cells in the human…